Diabetes, Metabolic Syndrome and Cardiovascular Disease

Title	Published	Price
United States Type 2 Diabetes Market By: Intellent Intellent's new industry report focuses on the US type 2 diabetes market. This report provides valuable insight and access to the competitive information and analysis necessary to make decisions regarding the direction of the market \| more... Search inside this report	11/14/2009	$7,500.00
UAE Healthcare Sector Forecast to 2012 By: RNCOS The UAE has emerged as one the fastest growing healthcare markets in the Middle East. The country’s healthcare sector has grown at double digit rate to keep pace with incessantly rising demand for quality treatment \| more...	11/1/2009	$1,000.00
Antidiabetics in Australia Market Forecast By: Datamonitor Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest \| more...	10/20/2009	$5,700.00
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes By: Datamonitor Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest \| more...	10/20/2009	$5,700.00
Antidiabetics Market Forecast By: Datamonitor Introduction Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, \| more...	10/8/2009	$15,200.00
Commercial Insight: Antidiabetics - DPP-IV inhibitors poised to sweep the market By: Datamonitor Introduction Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, \| more...	10/2/2009	$15,200.00
Diabetes R & D Pipeline: PPAR Agonists By: BioPolaris Diabetes is a chronic disease that may reduce life expectancy by as much as 15 years because high blood glucose levels can damage blood vessels and nerves. The International Diabetes Institute (Australia) estimates that direct \| more... Search inside this report	10/1/2009	$650.00
Minimally Invasive and Non Invasive Surgery Market (2009 - 2014) By: MarketsandMarkets The healthcare industry has recently witnessed the adoption of many new technologies that increase the efficiency of various medical treatments. Minimally invasive surgery (MIS) is one of the most important developments among all such cutting-edge \| more...	10/1/2009	$4,650.00
Diabetes R & D Pipeline: GLP-1 Agonists, Analogs and Allosteric Modulators By: BioPolaris The worldwide market for anti-diabetic therapeutic products is large and highly competitive. The global antidiabetic market is estimated to be over $24 billion in 2008. The largest players in this market are AstraZeneca plc (UK), \| more... Search inside this report	10/1/2009	$950.00
Metabolic Endocrinology Type II Diabetes Therapy Area Pipeline Report By: Life Science Analytics (LSA) Life Science Analytics', Type II Diabetes Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of type ii diabetes drugs by company and by \| more... Search inside this report	9/14/2009	$1,495.00

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 4